Puma Biotechnology Inc (PBYI)
5.31
-0.27
(-4.84%)
USD |
NASDAQ |
Mar 28, 16:00
5.31
0.00 (0.00%)
After-Hours: 20:00
Puma Biotechnology Price to Book Value: 4.790 for March 28, 2024
Price to Book Value Chart
Historical Price to Book Value Data
Date | Value |
---|---|
March 28, 2024 | 4.790 |
March 27, 2024 | 5.033 |
March 26, 2024 | 5.052 |
March 25, 2024 | 5.042 |
March 22, 2024 | 4.808 |
March 21, 2024 | 4.826 |
March 20, 2024 | 4.235 |
March 19, 2024 | 3.879 |
March 18, 2024 | 4.204 |
March 15, 2024 | 4.510 |
March 14, 2024 | 4.709 |
March 13, 2024 | 4.808 |
March 12, 2024 | 4.826 |
March 11, 2024 | 4.952 |
March 08, 2024 | 4.826 |
March 07, 2024 | 5.187 |
March 06, 2024 | 4.988 |
March 05, 2024 | 4.673 |
March 04, 2024 | 4.835 |
March 01, 2024 | 5.313 |
February 29, 2024 | 5.611 |
February 28, 2024 | 5.954 |
February 27, 2024 | 5.827 |
February 26, 2024 | 5.845 |
February 23, 2024 | 5.840 |
Date | Value |
---|---|
February 22, 2024 | 5.269 |
February 21, 2024 | 5.804 |
February 20, 2024 | 6.054 |
February 16, 2024 | 6.339 |
February 15, 2024 | 6.232 |
February 14, 2024 | 6.598 |
February 13, 2024 | 5.537 |
February 12, 2024 | 5.670 |
February 09, 2024 | 5.153 |
February 08, 2024 | 4.819 |
February 07, 2024 | 4.494 |
February 06, 2024 | 4.476 |
February 05, 2024 | 4.351 |
February 02, 2024 | 4.208 |
February 01, 2024 | 4.360 |
January 31, 2024 | 4.190 |
January 30, 2024 | 4.248 |
January 29, 2024 | 4.44 |
January 26, 2024 | 4.342 |
January 25, 2024 | 4.413 |
January 24, 2024 | 4.458 |
January 23, 2024 | 4.467 |
January 22, 2024 | 4.44 |
January 19, 2024 | 4.199 |
January 18, 2024 | 4.565 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
2.737
Minimum
Oct 25 2023
55.58
Maximum
May 13 2020
14.65
Average
11.43
Median
Price to Book Value Benchmarks
ADMA Biologics Inc | 11.14 |
Regeneron Pharmaceuticals Inc | 4.066 |
CytomX Therapeutics Inc | -- |
Entrada Therapeutics Inc | 1.962 |
Sarepta Therapeutics Inc | 14.14 |
Price to Book Value Related Metrics
PE Ratio | 11.80 |
PS Ratio | 1.072 |
Price to Free Cash Flow | 17.57 |
Price | 5.31 |
Earnings Yield | 8.47% |
Market Cap | 255.98M |
Operating PE Ratio | 7.590 |
Normalized PE Ratio | 11.48 |